Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In collaboration with Cambodian authorities, MORU are running the Village Drama Against Malaria project for the third year. The project, which runs in 10 remote villages in March 2018, aims to create awareness about malaria prevention and early treatment.

2 children on stage during a theatre performance

In collaboration with Cambodian authorities and a local Cambodia theatre group, MORU are running the Village Drama Against Malaria project in Siem Pang district, Stung Treng province. This is the third year we are running this project. The project runs from 25th Feb to 29th March 2018 and will be in 10 villages, some of them very remote farming villages with close to the border with Laos along the Sikong river. Most of these villages are remote and populated by Lao and other ethnic minority peoples. 

The aim of the project is to create awareness about malaria prevention and early treatment; and infant vaccination using art and theater as engagement tools and leveraging traditional ethnic arts.

The theatre group goes from one village to another conducting art and theatre workshops with village children and young people. They also invite villagers to share their traditional tools, costumes. arts and dances. On the third evening, there is a public performance at the village square where there are games, singing competitions, malaria quizzes, and a comedy sketch about malaria – performed by village children.

The project is led by Nou Sanann (Public Engagement Officer) with support from Pich Kunthea, Tom Peto, Rupam Tripura, James Callery and Phaik Yeong Cheah, and is funded by a Wellcome Trust Provision for Public Engagement grant (supplement).

Similar stories

Incomplete reporting of COVID-19 disease severity criteria compromises meta-analysis

Patients affected by COVID-19 should be treated according to the severity of their disease. However, not all key national or international organisations define severity in the same way. This imprecision in severity assessment compromises the validity of some therapeutic recommendations. Using individual patient data would better guide and improve therapeutic recommendations for COVID-19.

Field evaluation of EasyScan GO: a digital malaria microscopy device

Microscopic examination of Giemsa-stained blood films is key to quantifying and detecting malaria parasites but there can be difficulties in ensuring both a high-quality manual reading and inter-reader reliability. The EasyScan GO was developed as a potential solution to this, a microscopy device using machine-learning-based image analysis for automated parasite detection and quantification.

Congratulations Professor Sir David Warrell, appointed Knight Commander of the Order of St Michael and St George

David Warrell, our founding director, has been appointed by the Queen ‘Knight Commander of the Order of St Michael and St George for services to global Health Research and Clinical Practice’. Please join us in congratulating Sir David on receiving this richly deserved high honour!

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Largest-ever IPD meta-analysis of malaria patients to inform haemoglobin changes

A new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published in BMC Medicine by the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group